Search

everythinglearnresearchcommunity

for

Search:↓

Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.

Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.

The FDA approved a new Pfizer drug for hair loss in teens.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

GLP1-RAs may have higher reports of suicidal events and hair loss compared to other diabetes drugs.

Membership in a self-help organization is linked to being better informed and having a higher education, but it doesn't clearly affect disease outcomes.

Olumiant should be covered for severe alopecia areata if certain conditions are met.

Simvastatin/ezetimibe may help some patients with severe alopecia areata regrow hair.

Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.

Immunoadsorption successfully treated a man's resistant polymyositis.

The formulated gel is a promising treatment for alopecia areata.

The gel improves hair regrowth and reduces irritation in alopecia areata treatment.

Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.

The new micelle formulation delivers acne treatment more effectively and safely than current gels.

Enzyme replacement therapy improved multiple symptoms of homocystinuria in mice.

Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.

Acitretin moderately improved skin and eye issues but not hair loss or light sensitivity in a 3-year-old with IFAP syndrome.

Tofacitinib may help treat nail dystrophy, especially when other treatments fail.

Tofacitinib shows promise for treating alopecia areata with significant hair regrowth and mild side effects.

Using regulatory T cells and Rapamycin together improves chronic graft-versus-host disease treatment outcomes in mice.

Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.

Upadacitinib effectively treats severe alopecia areata and is safe.

Both treatments for alopecia areata are equally effective and safe.

Baricitinib may effectively treat oral lichen planus.

Filgotinib completely reversed hair loss in a patient with rheumatoid arthritis and alopecia universalis.

Etretinate has only moderate effects on localized scleroderma and lichen sclerosus.

A woman with severe angioedema improved significantly after treatment with rituximab.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

GI197111X is best dissolved in Capmul MCM for trials.